Site Search
534 Results (showing 1 - 25)
Jul 31, 2009
DxS Teams with AstraZeneca on Iressa Companion Dx
DxS' TheraScreen EGFR29 Mutation Kit will be used to test the mutation status of patients' EGFR oncogene to identify their eligibility for treatment with Iressa.
Jul 31, 2009
Life Technologies Acquires Cytonix
Life Technologies disclosed the acquisition in its second-quarter earnings release. It said that it bought the firm for its intellectual property related to its microfluidics-based digital polymerase chain reaction technology.
Jul 31, 2009
NIH to Fund Grants to Support HLA Genomics Consortium
The grants will support studies of a gene complex associated with immune-mediated diseases.
Jul 31, 2009
Zebrafish Gene Expression Study Offers Clues to Drug Addiction
Using microarrays, a team of German and Dutch researchers has identified a set of genes that appear to contribute to amphetamine-response in zebrafish.
Jul 31, 2009
NIAID Offering $10.3M for Pathogen Dx, Therapeutics
The program will fund partnerships to develop medical diagnostics through R01 and SBIR grants.
Jul 31, 2009
People In The News: Jul 31, 2009
Lapo Paladini was named chief marketing officer at PerkinElmer this week, while Gen-Probe's Carl Hull joined the board of directors of the California Healthcare Institute.
Jul 31, 2009
Strategic Diagnostics' Q2 Revenues Rise 5 Percent
The firm said that its revenue growth was partially due to a 16 percent increase in life science revenues.
Jul 31, 2009
This Week in Science: Jul 31, 2009
RNA polymerase in action, changing how graduate education is funded in the US, Pavel Pevzner on the importance of computational biology, and more.
Jul 31, 2009
Fast-Tracking Francis
The Senate Committee on Health, Education, Labor, and Pensions may bypass confirmation hearings for Francis Collins.
Jul 31, 2009
Are the Bugs Smashed on the Grill the Same?
Keith Robison laughs about a study of "windshield genomics."
Jul 31, 2009
NIH Budget Sausage-Making
The US Senate appropriations committee has approved a 1.4 percent increase to the NIH budget, nearly half as much as the House has OK'd.
Jul 31, 2009
Gen-Probe's Sales Up Slightly in Q2; Shares Fall
The company's gains in clinical diagnostics sales were offset by sagging blood screening sales.
Jul 31, 2009
Bruker Strikes Mass Spec Joint Venture in India
Bruker LabMate will have five service hubs throughout the country for industry and academic clients.
Jul 30, 2009
Beckman Coulter's Q2 Revenues Fall on Cash Instrument Sales Decline
Gains for Beckman Coulter's recurring revenues were offset by a decrease in cash instrument sales.
Jul 30, 2009
Cepheid's Product Sales up 2 Percent in Q2
While its total revenues were down 3 percent, the firm's clinical reagents sales grew 54 percent.
Jul 30, 2009
PerkinElmer's Q2 Revenues Drop 14 Percent; Shares Hit Hard
PerkinElmer's revenues fell amid conitnuing constraints on the capital equipment market.
Jul 30, 2009
NHS Starts Pilot Program to Increase Doctors' Genetics Knowledge
The $7 million program will begin a process of creating a National Health Service that is caught up on personalized medicine.
Jul 30, 2009
Currency Translation Hits Orchid Cellmark's Top Line
Excluding the impact of currency, Orchid Cellmark's revenues were up 9 percent for the quarter.
Jul 30, 2009
Team IDs Cell Type-Specific Expression Effects for Regulatory Variants
Using SNP and expression microarrays, a team of researchers from Switzerland, the UK, and the US has uncovered cell type-specific differences in regulatory variant function within three different human cell types.
Jul 30, 2009
NIA to Fund Gene, Phenotype Studies on Long Lives
The study will seek genetic and other traits of families that live long and healthy lives.
Jul 30, 2009
The acquisition is Agilent's largest in the life sciences space and continues a strategy by the firm to focus on that segment and its "transformation into a leading bio-analytical measurement company," its chief executive said.
Jul 30, 2009
Including the effects of currency exchange, the mass spec business fell 15 percent year over year — the steepest decline among the company’s four divisions.
Jul 30, 2009
Instruments sales were down 8 percent, but its Acquity UPLC system continued to gain traction in the market, and its recently launched Synapt G2 is receiving as strong a reception as any instrument launched by Waters in recent years, company officials said.
Jul 30, 2009
According to Frank Laukien, president and CEO of the company, "for our high performance mass spectrometry solutions, we continue to see healthy revenue and order growth year over year."